Use of fibrates in the management of hyperlipidemia in HIV-infected patients receiving HAART

Infection

Volumn 30, Issue 1, 2002, Pages 26-31

  Calza, L ^a   Manfredi, R ^a   Chiodo, F ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Fibrates; HIV infection; Hypercholesterolemia; Hypertriglyceridemia; Protease inhibitors

Indexed keywords

ANTILIPEMIC AGENT; ANTIRETROVIRUS AGENT; BEZAFIBRATE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; PROTEINASE INHIBITOR;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET THERAPY; DRUG EFFICACY; EXERCISE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL;

ANTILIPEMIC AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CHOLESTEROL; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; HYPERLIPIDEMIAS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TRIGLYCERIDES;

EID: 0036172271     PISSN: 03008126     EISSN: None     Source Type: Journal    
DOI: 10.1007/s15010-001-2052-3     Document Type: Article

References (60)

1. Plasma lipids in HIV-infected patients: A prospective study in 95 patients
2. Circulating interferon-α levels and hypertriglyceridemia in the acquired immunodeficiency syndrome
3. Hypocholesterolemia is associated with immune dysfunction in early human immunodeficiency virus-1 infection
4. Metabolic disorders among HIV-infected patients treated with protease inhibitors: A review
5. Hyperlipidemia and inhibitors of HIV protease
6. Nutritional alterations associated with HIV infection
7. A short-term study on the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease
8. Marked hyperlipidemia on ritonavir therapy
9. A syndrome of peripheral lipodystrophy, hyperlipidemia and insulin resistance due to HIV protease inhibitors
10. Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection
11. Protease inhibitor therapy-associated lipodystrophy, hypertriglyceridemia and diabetes mellitus
12. Management of dyslipidemia in patients with HIV disease
13. Antiretroviral therapy in adults. Updated recommendations of the International AIDS-Society-USA Panel
14. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study
15. How to manage metabolic complications of HIV therapy: What to do while we wait for answers
16. Hepatic microsomal enzyme induction, beta-oxidation, and cell proliferant following administration of clofibrate, gemfibrozil, or bezafibrate in the CD rat
17. Bezafibrate. An update of its pharmacology and use in the management of dyslipidemia
18. Visceral-abdominal fat accumulation associated with use of indinavir
19. Hyperlipidemia associated with protease inhibitor therapy
20. Visceral obesity, hypertriglyceridemia and hypercortisolism in a boy with perinatally acquired HIV infection receiving protease inhibitor-containing antiviral treatment
21. Metabolic abnormalities and body fat redistribution in HIV-1 infected patients: The lipodystrophy syndrome
22. Influence of protease inhibitor therapy on lipoprotein metabolism
23. HIV-1 protease inhibitor-associated partial lipodystrophy: Clinicopathologic review of 14 cases
24. Lipid abnormalities during saquinavir soft-gel-based highly active antiretroviral therapy
25. Endocrine and metabolic evaluation of human immunodeficiency virus-infected patients with evidence of protease inhibitor-associated lipodystrophy
26. "Buffalo hump" in HIV-1 infection
27. Lipodystrophy defined by a clinical score in HIV-infected men on highly active antiretroviral therapy: Correlation between dyslipidemia and steroid hormone alterations
28. Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: Preliminary results of the LIPOCO study
29. Preliminary guidelines for the evaluation and management of dyslipidemia in adults infected with human immunodeficiency virus and receiving antiretroviral therapy: Recommendations of the Adult AIDS Clinical Trial Group Cardiovascular Disease Focus Group
30. Hyperlipidemia associated with HIV protease inhibitor use: Pathophysiology, prevalence, risk factors and treatment
31. Diagnosis, prediction, and natural course of HIV-1 protease inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: A cohort study
32. Alterations in serum levels of lipids and lipoproteins with indinavir therapy in human immunodeficiency virus-infected patients
33. Lipid elevations during non-nucleoside RTI (NNRTI) therapy: A cross-sectional analysis
34. Marked hypertriglyceridemia associated with ritonavir therapy
35. HIV-protease inhibitors
36. Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy: A 5-year cohort study
37. Serum triglycerides, HIV infection, and highly active antiretroviral therapy, Aquitaine Cohort, France, 1996 to 1998
38. "Buffalo hump" in HIV-1 infection
39. Pathogenesis of HIV-1 protease inhibitor-associated peripheral lipodystrophy, hyperlipidemia, and insulin resistance
40. HIV protease inhibitors stimulate hepatic triglyceride synthesis
41. Coronary artery disease and human immunodeficiency virus infection
42. Severe premature coronary artery disease with protease inhibitors
43. Myocardial infarction in HIV-infected men receiving protease inhibitors
44. Vascular complications associated with use of HIV protease inhibitors
45. Vascular complications associated with use of HIV protease inhibitors
46. Acute pancreatitis as a complication of ritonavir therapy in a patient with AIDS
47. Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy
48. Acceleration of confirmed coronary artery disease among HIV-infected patients on potent antiretroviral therapy
49. Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid
50. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole
51. Effects of itraconazole on the pharmacokinetics of atorvastatin
52. Rational assessment of the interaction profile of cerivastatin supports its low propensity for drug interactions
53. In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isoenzyme (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors
54. Efficacy and tolerability of pravastatin for the treatment of HIV-1 protease inhibitor-associated hyperlipidemia: A pilot study
55. Safety and efficacy of HMG-CoA reductase inhibitors for treatment of hyperlipidemia in patients with HIV infection
56. Use of fenofibrate in the management of protease inhibitor-associated lipid abnormalities
57. Nicotinic acid as therapy for dyslipidemia in non-insulin dependent diabetes mellitus
58. Increased beta-cell secretory capacity as mechanism for islet adaptation to nicotinic acid-induced insulin resistance
59. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol
60. Drug treatment of lipid disorders